Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Treatment by linezolid of lung TB caused by drug resistant mycobacterium (MBT) Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Clinical experience of clofazimine in the treatment of MDR-TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
In vitro susceptibility of TB- and MDR-TB-strains against linezolid at a local center in Berlin/GermanySource: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013
Efficacy of moxifloxacin instead of ethambutol in the intensive phase of therapy in newly diagnosed pulmonary TB Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Active drug-safety monitoring and management for tuberculosis patients treated with bedaquiline and linezolid, Belarus – 2014-2016 Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Efficiency of MDR-TB therapy with the use of thioureidoiminomethylpyridinii perchlorate Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Plasma concentration of isoniazid and rifampin in new tuberculosis patients with and without diabetes mellitus Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Safety and efficacy of linezolid, clarithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006
Linezolid in the treatment of patients with MDR TB and XDR TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Evaluation of optimal regimens for treatment of rifampicin resistant-tuberculosis: Multicenter, randomized controlled study in China Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Active pharmacovigilance for multidrug-resistant tuberculosis patients treated with Linezolid, Belarus – 2014-2015 Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015